CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 561 enrolled
Drug / intervention
Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccinebiological
Likely dose
Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02514746
NCT02514746Phase 4Completed
CompareCT.gov

Assessment of Long Term Immunogenicity of Japanese Encephalitis Live Attenuated SA-14-14-2 Vaccine in Previously Vaccinated Bangladeshi Children and Antibody Response and Safety to a Booster Dose

PATH·interventional·Posted Aug 4, 2015·Updated Oct 19, 2020

In Brief

A Phase 4 clinical trial evaluating Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine for Encephalitis, Japanese. Completed, enrolled 561 participants.

Detailed Summary

This study aims to understand the persistence of the Japanese encephalitis (JE) antibody response in previously vaccinated children. The proposed study will enrol Bangladeshi children who had previously participated in a lot to lot consistency study (JEV05; NCT01567865) of JE live attenuated SA 14-14-2 vaccine (CD-JEV).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEncephalitis, Japanese
Countries--
CollaboratorsInternational Centre for Diarrhoeal Disease Research, Bangladesh

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 4, 2015
Enrollment StartJul 30, 2015
Primary CompletionDec 15, 2016
Study CompletionJan 12, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.9 years ago

Interventions

Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccinebiological

0.5 mL subcutaneous injection